Remedium Lifecare Enhances R&D and CDMO, Secures ?182.7 Crore Export Deal
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Remedium Lifecare is upgrading its Contract Development and Manufacturing Organization (CDMO) services and R&D capabilities, marking its transition from a pharma raw material trader to an integrated pharmaceutical solutions provider. No new manufacturing capacity is being added, but the company is installing advanced testing equipment and expanding lab space for R&D and CDMO projects. The company recently secured a ₹182.7 crore multi-year export contract with a leading pharmaceutical distributor in the UK and Europe. On day 8 of its rights issue, the company received about 50% subscription worth ₹24.28 crores (shares priced at ₹1 each), with the issue closing on May 14, 2025. Additionally, its Singapore subsidiary Remlife Global has partnered with JiyaYu Lifesciences to license green chemistry technology that replaces animal-origin raw materials in API manufacturing with sustainable bioprocesses.
The large export contract and move into higher-margin CDMO services could boost future revenue and margins, which is a positive signal for shareholders. However, the rights issue had only ~50% subscription by day 8, suggesting moderate investor appetite, so investors should watch the final subscription outcome and execution of the export deal.